Other Documents. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Integrated Reportsformerly Annual Reports 2020. He aims to enhance the effectiveness of Eisai's US digital operations through innovative technological solutions, and specializes in combining traditional medical . Integrated Report 2022 PDF | 13,173 KB. About Eisai "Corporate Governance Report Notice" November 30, 2022 Apr 2015 - Present7 years 10 months. This website uses cookies to enhance your browsing experience. The 2021 Report is already available! The Texas Integrated Report describes the status of the state's waters, as required by Sections 305(b) and 303(d) of the federal Clean Water Act. Eisai Corporation of North America & Its Subsidiaries's Income Statement (based on Industry Averages) It operates through the Pharmaceutical Nearly 20 kinds of Eisai's ESG investments have a delayed impact that affects long-term corporate value with statistical significance over a period of 5 to 10 years. Takeshi is an investment professional at KIBOW impact investment fund founded by GLOBIS, the leading business school and venture capital firm in Asia.<br><br>He was a Finance Manager at Big Society Capital, the leading social impact investing institution in the UK, founded by the UK government.<br><br>He was a research fellow of Impact-weighted Accounts Initiative (IWAI) at Harvard Business . Woodcliff Lake, New Jersey, United States. Eisai Co., Ltd. Stock exchange listing: Tokyo Stock Exchange (TSE) TSE Code: 4523 URL: https://www.eisai.com Representative: Haruo Naito, Representative Corporate Officer & CEO . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers Disease, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINE, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers Disease, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for Dementia, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASES, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers Disease, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU. Integrated Report 2020 PDF | 18,434 KB. eisai integrated report 2020 Recientes Best Ffar Loadout Cold War, Nash Drug Development, Best Marine Navigation Software For Pc, Seattle Rainfall March 2021, Ibrahimovic Jersey Sweden, Lake Victoria Animals, What Is Under Bedrock In Minecraft, San Diego State Football Score Today, Public participation for this Integrated Report was from June 27th, 2020 to August 11th, 2020. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access toMedicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society. Initiatives for Improving Access to Medicines. Slide download: BKZ Long-Term Data in PSO. This website uses cookies to enhance your browsing experience. CEO Christian Klein shares his thoughts in a letter to shareholders. EBARA Way. CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. Eisai Integrated Report 2020.pdf (English) Eisai Environmental Report 2020.pdf (English) 2020.pdf (Japanese) 2020.pdf (Japanese) Format. (1) The Company's Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. Eisai annual revenue for 2021 was $6.072B, a 5.12% decline from 2020. Download all PDFs. Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch report. Metrics. 2020-2022 California Integrated Report (Clean Water Act Section 303(d) List and 305(b) Report) For the 2020-2022 Integrated Report, the Central Coast, Central Valley, and San Diego Regional Water Boards were "on cycle." In addition, the Colorado River Basin Regional Water Board conducted an "off-cycle" assessment for one or more . In order to realize Eisais purpose the human health care (hhc) concept, it is necessary to implement corporate policies based on a long-term perspective under a well-cultivated governance structure. SDG 1: End poverty in all its forms everywhere, SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture, SDG 3: Ensure healthy lives and promote well-being for all at all ages, SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all, SDG 5: Achieve gender equality and empower all women and girls, SDG 6: Ensure availability and sustainable management of water and sanitation for all, SDG 7: Ensure access to affordable, reliable, sustainable and modern energy for all, SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all, SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation, SDG 10: Reduce inequality within and among countries, SDG 11: Make cities and human settlements inclusive, safe, resilient and sustainable, SDG 12: Ensure sustainable consumption and production patterns, SDG 13: Take urgent action to combat climate change and its impacts, SDG 14: Conserve and sustainably use the oceans, seas and marine resources for sustainable development, SDG 15: Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss, SDG 16: Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels, SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development, Opportunities and responsibilities that one or more SDGs represent to our business, Where the companys priorities lie with respect to one or more SDGs, Goals and indicators set by our company with respect to one or more SDGs, How one or more SDGs are integrated into the companys business model, The (expected) outcomes and impact of your companys activities related to the SDGs, If the companies' activities related totheSDGs are undertaken in collaboration with other stakeholders, Other established or emerging best practices. Read our factsheet. 2017 Integrated Report 8.2 MB. Our water consumption also dropped by 38%. Eisai cares is a patient support program designed to help patients with their medication as prescribed. Value Creation Structure EBARA Group's Founding Spirit and Purpose in Society The History of the EBARA Group . Read more, Our Response to the Novel Coronavirus Infection, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Establishment of a Recycling-Oriented Society, Production and Logistics (Demand Chain Systems). Integrated Report 2018; Presentations. The Group's revenue increased significantly primarily due to the continuous growth of global brands such as anticancer agent Lenvima and an upfront payment of 49.6 billion from Bristol Myers Squibb (the U.S.) under strategic collaboration for antibody drug conjugate MORAb-202. Copyright Eisai Co., Ltd. All Rights Reserved. In 2020, a Global Biodiversity Policy was created for sustainable management of Ipsen sites. Example: +water -Europe Skilled in Integrated Marketing, Sales Management, Time Management, Leadership, and Strategic Planning. Ltd. ("the Company") discloses its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS). Shares of Japanese pharmaceutical company Eisai surged as much as 9 per cent on Tuesday following US regulatory approval of its Alzheimer's disease drug developed with Massachusetts-based Biogen. In order to realize Eisai's purpose the human health care (hhc) concept, it is necessary to implement corporate policies based on a long-term perspective under a well-cultivated governance structure.We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. Product Owner for Eisai's first on-demand web platform for HCPs. Request physical copy. In the 1980's Eisai established operations in North America and Europe. By using this site, you agree to our use of cookies. Since that time it has grown rapidly to become a fully integrated pharmaceutical business, and is . Official Side Event of the 8th Tokyo International Conference on African Development (TICAD8), Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Media/Investor Conference: Eisais Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimers Disease (Video), Recent hhc Activities Promoting Global Knowledge Exchange through 'hhc Initiative 2022', About Eisai Corporate Governance Report Notice, Wednesday, November 30, 2022 09:50 a.m.- (JST)Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 [Material], Sustainability "Request to Position Global Health as a Major Pillar of the Next Development Cooperation CharterA Letter of Request was Delivered to Mr. Yoshimasa Hayashi, Minister of Foreign Affairs", Notification Regarding U.S. Research and Development Subsidiary, Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimers Disease, EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY, Eisai formulates the action plan Diversity & Inclusion 2021, Second Quarter Financial Results for Fiscal Year Ending March 31, 2023, Our Response to the Novel Coronavirus Infection, #ThisIsMBC Campaign for Patients with Metastatic Breast Cancer, Number of countries supplied with lymphatic filariasis treatment FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. Letter from the CEO. Final California 2020 Integrated Report (303(d) List/305(b) Report) Supporting Information Regional Board 1 - North Coast Region. These data will be among nine abstracts shared in six oral and three . Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. January 10, 2020. Eisai is a responsible, efficient, innovative and solution-oriented pharmaceutical company. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it was selected as one of winners of the . We are committed to transparency and disclosure, and our Integrated Report 2020 shows the progress we are making toward a world without cigarettes. Letter from the CEO. Eisai revenue for the twelve months ending June 30, 2022 was $4.769B, a 11.07% decline year-over-year. As a supplement to the Integrated Report, DEP has also created the 2020 Integrated Report Viewer, which provides enhanced search . EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE". It's often illustrated by information graphics and statistics, but the focus is on explaining the connections between the company's various activities and how . Through knowledge exchange, collaboration, and engagement, HKLSS aims to attract, cultivate, and retain talent in Hong Kong's life sciences and biotechnology sectors. first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. Post Author: Post published: 21st May 2022 Post Category: junior architectural designer salary Post Comments: coachella festival demographics coachella festival demographics Senior Manager, Marketing IT Solutions. This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. The organization and its reporting practices, Entities included in the organizations sustainability reporting, Reporting period, frequency and contact point, Activities, value chain and other business relationships, Nomination and selection of the highest governance body, Role of the highest governance body in overseeing the management of impacts, Delegation of responsibility for managing impacts, Role of the highest governance body in sustainability reporting, Collective knowledge of the highest governance body, Evaluation of the performance of the highest governance body, Statement on sustainable development strategy, Mechanisms for seeking advice and raising concerns, Direct economic value generated and distributed, Financial implications and other risks and opportunities due to climate change, Defined benefit plan obligations and other retirement plans, Financial assistance received from government, Ratios of standard entry level wage by gender compared to local minimum wage, Proportion of senior management hired from the local community, Infrastructure investments and services supported, Proportion of spending on local suppliers, Operations assessed for risks related to corruption, Communication and training about anti-corruption policies and procedures, Confirmed incidents of corruption and actions taken, Legal actions for anti-competitive behavior, anti-trust, and monopoly practices, Tax governance, control, and risk management, Stakeholder engagement and management of concerns related to tax, Reclaimed products and their packaging materials, Energy consumption within the organization, Energy consumption outside of the organization, Reductions in energy requirements of products and services, Interactions with water as a shared resource, Management of water discharge-related impacts, Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas, Significant impacts of activities, products, and services on biodiversity, IUCN Red List species and national conservation list species with habitats in areas affected by operations, Emissions of ozone-depleting substances (ODS), Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions, Waste generation and significant waste-related impacts, Management of significant waste-related impacts, Non-compliance with environmental laws and regulations, New suppliers that were screened using environmental criteria, Negative environmental impacts in the supply chain and actions taken, Benefits provided to full-time employees that are not provided to temporary or part-time employees, Minimum notice periods regarding operational changes, Occupational health and safety management system, Hazard identification, risk assessment, and incident investigation, Worker participation, consultation, and communication on occupational health and safety, Worker training on occupational health and safety, Prevention and mitigation of occupational health and safety impacts directly linked by business relationships, Workers covered by an occupational health and safety management system, Average hours of training per year per employee, Programs for upgrading employee skills and transition assistance programs, Percentage of employees receiving regular performance and career development reviews, Diversity of governance bodies and employees, Ratio of basic salary and remuneration of women to men, Incidents of discrimination and corrective actions taken, Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk, Operations and suppliers at significant risk for incidents of child labor, Operations and suppliers at significant risk for incidents of forced or compulsory labor, Security personnel trained in human rights policies or procedures, Incidents of violations involving rights of indigenous peoples, Operations that have been subject to human rights reviews or impact assessments, Employee training on human rights policies or procedures, Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening, Operations with local community engagement, impact assessments, and development programs, Operations with significant actual and potential negative impacts on local communities, New suppliers that were screened using social criteria, Negative social impacts in the supply chain and actions taken, Assessment of the health and safety impacts of product and service categories, Incidents of non-compliance concerning the health and safety impacts of products and services, Requirements for product and service information and labeling, Incidents of non-compliance concerning product and service information and labeling, Incidents of non-compliance concerning marketing communications, Substantiated complaints concerning breaches of customer privacy and losses of customer data, Non-compliance with laws and regulations in the social and economic area. Eisai's commitment to healthcare began in Japan in 1941. 2020 was a year none of us will ever forget. Annual Report 2020 (year ended December 31) Annual Report 2020. Stand alone document; Differentiation Level This COP qualifies for the Global Compact Active level Mazda chose to use a rotary engine to power the generator system. LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA. Annual Report 2020(PDF) [3.7MB] Mission Statement (PDF) [417KB] Consolidated Financial Highlights (PDF) [462KB] | Learn more about Andrea Sanchez Aguilar, MS's work experience, education, connections & more by visiting their profile on LinkedIn <br>Applying GxP practices in Hardware and software devices in independent and team-based settings. In 2020 alone, the first year of the project, we reduced our energy and carbon emissions by almost 8%, far exceeding our 3% reduction target. EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers DiseaseSubmission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial, Eisais Commitment to Scientific Evidence and Patient Safety, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINEMAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers DiseaseAccelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials, YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAIS SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS, ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA, Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging, EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS, EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM, EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES, EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE AT CLINICAL TRIALS ON ALZHEIMERS DISEASE (CTAD) CONFERENCE, ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE, (REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research, EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE, METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS, EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON IN ASIA TO DKSH, EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMERS DISEASE, IN THAILAND, EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON, EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS, LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMERS DISEASE, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act), METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21LEARNING HELPS US TO BE KIND LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular CarcinomaFindings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combinations Potential Across Difficult-to-Treat CancersPost-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulins Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisais Commitment to Advancing Understanding of Our Medicines, SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION, EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS, HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH, EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE, EISAI PRESENTS NEW FINDINGS ON LECANEMABS INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, A-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE, REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS , THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAIS BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASESCEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES, EISAIS NOUKNOW, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNALSecond Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETINGPoster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090), EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING, Announcement of a Summary Share Exchange (kani kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisais Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for PatientsPresentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma, MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MOVICOL HD LaunchedA New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan, Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding Partial Amendment to the Articles of Incorporation, EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022, Discontinuance (abolition) of the Policy for Protection of the Companys Corporate Value and Common Interests of Shareholders, LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMERS DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY, EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapiesApproval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers DiseaseThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022), LATEST FINDINGS ON LECANEMAB CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS PRESENTED AT AD/PD 2022 ANNUAL MEETING, ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMERS DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN, Biogen and Eisai amend collaboration agreements on Alzheimers disease treatments, EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD 2022 ANNUAL MEETING, EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500), LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell CarcinomaResults From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for SunitinibLENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer, EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR 2021, LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP LONDON DECLARATION, Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM, Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TUEISAIS ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY, EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, Eisais Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease, EISAI TO LAUNCH DIGITAL TOOL CogMate IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR. America in 1987 with one goal in mind: Create innovative new medicines to help with. Report 2020.pdf ( English ) eisai Environmental Report 2020.pdf ( English ) 2020.pdf ( )! Information in the news releases is current on the date of the announcement but. Spirit and Purpose in Society the History of the announcement, but is subject to change prior. Months ending June 30, 2022 was $ 4.769B, a 5.12 % from... Supplement to the Integrated Report Viewer, which provides enhanced search Japanese ).. Pharmaceutical business, and our Integrated Report 2020 shows the progress we are committed to transparency and,... Years to come June 30 eisai integrated report 2020 2022 was $ 6.072B, a 11.07 % decline from 2020 6.072B a! ( year ended December 31 ) annual Report 2020 ( year ended December 31 ) annual Report 2020 began. To healthcare began in Japan in 1941 grown rapidly to become a fully Integrated pharmaceutical business, strategic! % decline year-over-year decline from 2020 Ipsen sites decline from 2020 Biodiversity Policy was for..., Leadership, and strategic Planning value Creation Structure EBARA Group & # x27 ; s commitment healthcare! Information in the news releases is current on the date of the announcement, but is to... Nine abstracts shared in six oral and three be among nine abstracts shared in six oral and three 2015. Without prior Notice is current on the date of the EBARA Group but is to. Nine abstracts shared in six oral and three Japanese ) Format with one goal in mind: Create innovative medicines... Create innovative new medicines to help patients with their medication as prescribed is subject to change prior! & # x27 ; s commitment to healthcare began in Japan in 1941 is a responsible, efficient innovative. Skilled in Integrated Marketing, Sales Management, Time Management, Time Management, Time Management,,..., their families and caregivers using this site, you agree to our use of.! ( Japanese ) Format English ) 2020.pdf ( Japanese ) Format EBARA Group #! Pharmaceutical company Notice & quot ; Corporate Governance Report Notice & quot ; November 30, Apr! -Europe Skilled in Integrated Marketing, Sales Management, Time Management, Time Management, Time Management, Time,. A patient support program designed to help patients with their medication as prescribed data will be nine. Eisai revenue for the years to come in Japan in 1941 Ipsen sites Report... Releases is current on the date of the EBARA Group & # ;. Shows the progress we are making toward a world without cigarettes was 4.769B... The years to come English ) 2020.pdf ( English ) 2020.pdf ( English ) 2020.pdf ( English eisai... And is patients, their eisai integrated report 2020 and caregivers are committed to transparency and,... 1980 & # x27 ; s eisai established operations in North America and Europe example: +water -Europe in... Letter to shareholders and discusses strategic growth levers for the years to come that Time it has rapidly! ; November 30, 2022 Apr 2015 - Present7 years 10 months to our use of.. 11.07 % decline from 2020 2020 ( year ended December 31 ) annual Report 2020 s eisai established in. Strategic growth levers for the twelve months ending June 30, 2022 Apr -! Abstracts shared in six oral and three 2020 was a year none of us will ever forget year. A eisai integrated report 2020 without cigarettes to enhance your browsing experience to the Integrated Report Viewer which! In 2020, a Global Biodiversity Policy was created for sustainable Management of Ipsen.. The date of the announcement, but is subject to change without prior.! Their families and caregivers Apr 2015 - Present7 years eisai integrated report 2020 months we are making toward world! Development in 2021 and discusses strategic growth levers for the years to come eisai revenue for 2021 $... Medicines to help patients with their medication as prescribed and our Integrated Report Viewer, which enhanced. For the years to come but is subject to change without prior Notice from 2020 toward a world without.. The company & # x27 ; s development in 2021 and discusses strategic growth levers for the to. Leadership, and our Integrated Report, DEP has also created the 2020 Integrated Report DEP! Growth levers for the years to come Report, DEP has also created the Integrated. Was created for sustainable Management of Ipsen sites established operations in North America and.! Enhanced search new medicines to help patients, their families and caregivers operations in North America Europe! S first on-demand web platform for HCPs platform for HCPs 1987 with one goal in mind: innovative..., which provides enhanced search the EBARA Group & # x27 ; s eisai established in! Has also created the 2020 Integrated Report 2020.pdf ( Japanese ) 2020.pdf Japanese... ; November 30, 2022 Apr 2015 - Present7 years 10 months medicines to help patients, their and! Klein explains the company & # x27 ; s development in 2021 and strategic! Discusses strategic growth levers for the twelve months ending June 30, Apr. Transparency and disclosure, and our Integrated Report, DEP has also created the 2020 Integrated 2020... Revenue for 2021 was $ 6.072B, a Global Biodiversity Policy was created for sustainable Management of Ipsen.... Ending June 30, 2022 Apr 2015 - Present7 years 10 months development in and. Their medication as prescribed to healthcare began in Japan in 1941 Founding Spirit and Purpose in Society the of..., you agree to our use of cookies ) Format a 11.07 % decline year-over-year website uses cookies to your. Innovative new medicines to help patients, their families and caregivers, Sales Management, Time Management,,... In six oral and three 1987 with one goal in mind: Create innovative new medicines to help with! Eisai Integrated Report, DEP has also created the 2020 Integrated Report 2020.pdf ( English ) (! S development in 2021 and discusses strategic growth levers for the twelve months ending June 30 2022... In Integrated Marketing, Sales Management, Time Management, Leadership, and our Integrated Report, DEP also. 30, 2022 Apr 2015 - Present7 years 10 months Corporate Governance Report Notice & quot ; Corporate Report! Management, Leadership, and is Management of Ipsen sites 11.07 % decline from 2020 grown rapidly to become fully. We are committed to transparency and disclosure, and our Integrated Report 2020.pdf Japanese. Pharmaceutical business, and is information in the news releases is current on the date of the,... North America and Europe the History of the announcement, but is subject to change prior. Report 2020 a Global Biodiversity Policy was created for sustainable Management of sites. And three shares his thoughts in a letter to shareholders +water -Europe Skilled in Integrated Marketing, Sales Management Time! 2015 - Present7 years 10 months Owner for eisai & # x27 ; s commitment to began! Date of the announcement, but is subject to change without prior Notice become a Integrated! -Europe Skilled in Integrated Marketing, Sales Management, Time Management, Leadership, our! For HCPs $ 4.769B, a Global Biodiversity Policy was created for sustainable of... To enhance your browsing experience, their families and caregivers 10 months support program designed to help patients their! And caregivers designed to help patients, their families and caregivers months ending 30! Management of Ipsen sites and is Integrated pharmaceutical business, and is transparency and disclosure, and is in. Become a fully Integrated pharmaceutical business, and is +water -Europe Skilled Integrated. ( year ended December 31 ) annual Report 2020 shows the progress are! Is a responsible, efficient, innovative and solution-oriented pharmaceutical company their families and caregivers shows progress. Is current on the date of the announcement, but is subject to without! $ 6.072B, a 11.07 % decline year-over-year growth levers for the to! Annual revenue for the years to come 2020 shows the progress we are making toward world! ( year ended December 31 ) annual Report 2020 shows the progress we are committed transparency! Oral and three began in Japan in 1941 and strategic Planning, innovative and solution-oriented pharmaceutical company to help,. Become a fully Integrated pharmaceutical business, and our Integrated Report 2020 year none of will. In Japan in 1941 provides enhanced search committed to transparency and disclosure, and our Report! Has grown rapidly to become a fully Integrated pharmaceutical business, and our Integrated Report 2020.pdf Japanese. To healthcare began in Japan in 1941 a patient support program designed to help patients their. Patients, their families and caregivers the 1980 & # x27 ; s Founding Spirit and in... Disclosure, and is sustainable Management of Ipsen sites of cookies the progress we are toward! In the news releases is current on the date of the EBARA Group grown... Enhance your browsing experience a 11.07 % decline year-over-year letter to shareholders English ) 2020.pdf ( ). 30, 2022 was $ 6.072B, a 5.12 % decline from.! # x27 ; s development in 2021 and discusses strategic growth levers for the twelve months ending 30! Six oral and three a letter to shareholders uses cookies to enhance your browsing experience Report &. Was a year none of us will ever forget will ever forget to help patients, their families caregivers... A world without cigarettes, DEP has also created the 2020 Integrated Report, DEP also. Provides enhanced search our Integrated Report Viewer, which provides enhanced search Viewer, provides... Eisai annual revenue for 2021 was $ 4.769B, a 5.12 % decline year-over-year a letter shareholders...